If you've been on testosterone therapy — or you've been circling the idea for a year, reading everything, deciding nothing — you may have caught a headline about the FDA changing the warning label.
Depending on which headline you caught, you came away with one of two impressions. Either testosterone was just cleared of the heart risk everyone worried about. Or testosterone was just slapped with a new blood pressure warning.
Both of those are half-true, which is another way of saying both are wrong.
Here's the honest version.
What the label used to say
For roughly a decade, testosterone products carried a boxed warning — the strongest kind the FDA issues — that included language about a possible increased risk of heart attack and stroke.
That language came from a period when the evidence was genuinely murky. A handful of observational studies had raised a flag. The flag was big enough that the FDA acted, but the data underneath it was never strong enough to settle the question. So the warning sat there for years, doing what an unresolved warning does: it scared some men off treatment they might have benefited from, and it did very little to help the men who took it anyway.
Doctors knew the evidence was thin. Patients mostly didn't. That gap is part of why so many men who feel awful never bring it up at all.
What changed, and why
In 2023, results came out from a trial called TRAVERSE. It was the study the field had been waiting for — a large, randomized, placebo-controlled trial designed specifically to answer the cardiovascular question rather than infer it.
It enrolled more than 5,000 middle-aged and older men who had both diagnosed hypogonadism (clinically low testosterone with symptoms) and existing cardiovascular disease or high cardiovascular risk. In other words: the men most likely to show a signal if a signal existed.
After a mean follow-up of about 33 months, the rate of the primary outcome — nonfatal heart attack, nonfatal stroke, or cardiovascular death — was 7.0% in the testosterone group and 7.3% in the placebo group. Testosterone met the trial's threshold for noninferiority. It did not increase major cardiac events in that population.
On the strength of that, the FDA removed the cardiovascular risk language from the boxed warning and required the TRAVERSE results to be added to the labeling of testosterone products across the class.
That's the good news, and it's real. It is not, however, the same as "testosterone is heart-healthy."
The part the celebratory headlines skipped
The same round of labeling changes added something new: a warning about blood pressure.
The FDA required class-wide labeling on increased blood pressure, based on postmarket ambulatory blood pressure monitoring studies. The measured effect is modest — over six months, mean systolic blood pressure rose about 0.3 mm Hg on testosterone versus a drop of about 1.5 mm Hg on placebo — but it's consistent enough that products without a blood pressure warning were required to add one.
TRAVERSE itself also flagged a few things that weren't in the headline number. Rates of pulmonary embolism, atrial fibrillation, and acute kidney injury were higher in the testosterone group than in the placebo group. The increases were numerical and not statistically significant in the main cardiovascular safety analysis, but they were considered “signals” that warranted ongoing monitoring in the study.
And the FDA kept one line intact that matters more than any of this: the Limitation of Use. Testosterone products are still not established as safe and effective for low testosterone caused by aging alone. This may change in the future as the FDA continues to monitor health care outcomes.
So what does this actually mean for you?
Read the change for what it is. The label got more precise, not more permissive.
Here's how we'd translate it for a real person sitting across from us:
- If you have genuine, confirmed hypogonadism, one of the biggest fears attached to treatment just got a much clearer answer. That's meaningful. It doesn't erase the need for monitoring — it removes a scarecrow that was standing where a real conversation should have been.
- If you have high blood pressure, or it runs close to the line, this is now an important part of the conversation. Not a disqualifier. Does it have a genetic component or lifestyle related or both. A thing to check, treat, and keep watching.
- If you have a history of clots, atrial fibrillation, or kidney disease, those belong on the table before anything is prescribed — not discovered three months in. Again, Not a disqualifier and does it have a genetic component or lifestyle related or both.
- If you feel run down and you're 52 and nobody has actually measured anything, this label change does not apply to you yet. The FDA is still saying, in plain language, that "I'm tired and older" isn't a diagnosis.
That last one is where most of the real risk lives. Not in the medication — in the shortcut around the workup.
The unglamorous part that actually protects you
A proper evaluation isn't complicated, but it is specific. Morning testosterone is drawn on more than one day, because levels swing.
A look at LH and FSH to understand where the problem originates.
Prolactin, thyroid, a complete blood count, and a look at hemoglobin and hematocrit, since testosterone can thicken the blood. Blood pressure measured properly, more than once.
A conversation about sleep, alcohol, weight, medications, lifestyle and stress — all of which can push testosterone down without any hormone problem being the root cause.
Then, if treatment makes sense, follow-up labs on a schedule instead of whenever you happen to think of it.
None of that is exciting. All of it is what makes the new label something you can actually stand on.
When it's worth getting evaluated
If you've had months of low energy, low drive, worsening mood, brain fog, loss of strength you can't train your way out of, or a change in sexual function — and it feels less like getting older and more like becoming someone else — that's worth investigating. Not because a prescription is the answer, but because you deserve to know what the answer is and available options to help you feel your best.
Sometimes it's testosterone. Sometimes it's disrupted sleep, thyroid, medication side effects, or depression wearing a costume. You can't tell from the outside, and neither can we until we look.
Schedule your free 30-minute consult
Please note: this blog post is for educational purposes only, not medical advice. Whether hormone testing or testosterone therapy is right for you depends on your health and history, and an evaluation with a qualified provider is the way to know.
Sources
- FDA, Drug Safety Communication: FDA issues class-wide labeling changes for testosterone products https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
- Urology Times, FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies https://www.urologytimes.com/view/fda-issues-label-changes-for-testosterone-products-following-traverse-post-market-studies
- Pharmacy Times, FDA Issues New Labeling Changes Clarifying Safety of Testosterone Products Following Clinical Trials https://www.pharmacytimes.com/view/fda-issues-new-labeling-changes-clarifying-safety-of-testosterone-products-following-clinical-trials
- Endocrinology Advisor, Cardiovascular Safety Data Prompt Label Changes for All Testosterone Replacement Products https://www.endocrinologyadvisor.com/news/cardiovascular-safety-data-prompt-label-changes-for-all-testosterone-replacement-products/